E arly brain injury (EBI) is the primary reason behind high rates of mortality and delayed neurological deficits in patients after subarachnoid hemorrhage (SAH).
Mitoquinone, a potent mitochondria-targeting antioxidant, which contains several hundred-fold antioxidant properties when compared with untargeted antioxidants, is effective in prevention of mitochondrial dysfunction. 5 Studies show that it effectively attenuates oxidative stress and apoptosis by repairing damaged mitochondria, 6 and is associated with induction of mitophagy. 7 However, mechanisms of mitoquinone treatment have never been investigated in the context of SAH. Furthermore, oxidative stress regulator complex Keap1 (Kelch-like epichlorohydrin-associated protein 1)/Nrf2 (nuclear factor-E2-related factor 2) has been identified to be the main target of antioxidants in various diseases, as well as in the SAH model. 8 Although mitoquinone has been reported to dissociate and active Nrf2 from aforementioned complex in kidney injury, 9 it still needs to be investigated after induction of SAH. We postulate that the Keap1/Nrf2 complex participates in the mitoquinone induced mitophagy after induction of SAH.
PHB2 (prohibitin 2), a mitophagy receptor that binds to the autophagosomal membrane-associated protein LC3II (light chain 3-II) and is a viable explanation underlying induction of mitophagy and establishment of protective effects against dysneuria. 10 Moreover, compared with traditional mitophagy markers PINK1 (phosphatase and tensin-induced kinase 1) and Parkin, 11 the role of PHB2 in mitophagy would be a worthwhile and a novel target to pursue as a therapeutic strategy for SAH.
Thus, we hypothesize that mitoquinone will inhibit oxidative stress and neuronal death via Nrf2/Keap1/PHB2 pathway in mitophagy after SAH in rats.
Methods
The authors declare that all supporting data are available within the article and in the online-only Data Supplement.
SAH Animal Model
Adult male Sprague-Dawley rats (weight 280-330 g) were housed in a 12/12 hours light/dark cycle room with humidity control, 25°C temperature, free access to food and water before surgery. The endovascular perforation SAH model was performed as reported previously. 12 All experiments were approved by the Institutional Animal Care and Use Committee of Loma Linda University, which in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Experimental Protocols

Experiment 1
Thirty-six (n=6 per group) rats were randomly divided into 6 groups: sham and SAH after 3, 6, 12, 24, 72 hours after SAH. Additionally, 6 rats (n=3 per group) were equally distributed to sham and SAH after 24-hour groups for double immunohistochemistry staining (n=3 per group). Expression of Keap1, Nrf2, PHB2, and LC3I/LC3II was analyzed by Western blot. Immunofluorescence staining was performed for colocalization with neurons ( Figure I in the online-only Data Supplement).
Experiment 2
In a short-term outcome evaluation, 30 (n=6 per group) rats were randomly assigned into 5 groups: sham, SAH+vehicle (1 mL of sterile 0.9 % of NaCl), SAH+mitoquinone 1 mg/kg, SAH+mitoquinone 3 mg/kg, SAH+mitoquinone 9 mg/kg groups for neurological scoring. Additionally, 9 (n=3 per group) rats were equally used in sham, SAH+vehicle, and SAH+mitoquinone-best dosage (3 mg/kg) groups for immunofluorescence, dihydroergotamine (DHE), and FluoroJade C (FJC) staining. SAH+mitoquinone-best dosage (3 mg/kg) was administered in experiments 3, 4, and 5.
Experiment 3
In a long-term outcome evaluation, 24 (n=8 per group) rats were equally divided into sham, SAH+vehicle, and SAH+mitoquinone groups. Long-term neurobehavioral experiments, Nissl, and FJC staining were performed.
Experiment 4
To investigate the proposed molecular mechanism, 24 (n=6 per group) rats were randomly divided into SAH+ML385+mitoquinone, SAH+dimethyl sulfoxide (DMSO)+mitoquinone, SAH+PHB2 small interfering RNA (siRNA)+mitoquinone, and SAH+scramble siRNA+mitoquinone groups for Western blot. Another 12 (n=3 per group) rats were used for DHE and FJC double staining. Samples of sham (n=6 per group), SAH+vehicle and SAH+mitoquinone groups (n=9 per group) were shared with experiment 2. Samples for malondialdehyde (MDA) measurement were using 10 mg from frozen brain samples prepared for Western blot in each group.
Experiment 5
Nuclear and mitochondrial proteins were gathered from 18 rats (6 rats per group) of sham, SAH+vehicle, and SAH+mitoquinone groups. Pathway related proteins were detected in their individual organelles with Western blot.
Drug Administration
Mitoquinone (MedKoo Biosciences, Morrisville, NC) was administered intraperitoneally after SAH. ML385 (AOBIOUS, Gloucester, MA), diluted in DMSO, was intracerebroventricularly injected before SAH. Both 500 pmol of PHB2 siRNA and scramble RNA (Origene Technologies, Inc, Rockville, MD) in 5 μL was injected intracerebroventricularly 48 hours presurgery as previously reported.
12
Severity of SAH
The severity of SAH was blindly measured using the SAH grading scale after euthanasia as previously described. 12 Rats with SAH grading scores ≤7 at 24 hours were excluded from this study.
Assessment of Short-Term Neurobehavioral Outcomes
Eighteen-point scoring system with a modified Garcia scale and another 4-point scoring system with beam balance test were utilized to blindly evaluate as previous described.
12
Assessment of Long-Term Neurobehavioral Outcomes
Foot fault test was performed in the first 3 weeks after SAH to evaluate sensorimotor coordination and balance as previously described. 13 At 21 to 25 days after SAH, rotarod and water maze tests were utilized as previous reported.
14
Western Blot
Left hemispheres of brain samples were collected without surface hematoma 24 hours after SAH. Western blot was performed as previous described.
12
Histomorphology Measurement
Double immunofluorescence, DHE, FJC were performed as previously described. 12, 14, 15 A series of 8-μm slices were prepared. Positive cells were counted in 6 sections per brain for the mean at ×200 magnification by an independent observer.
Nissl staining and evaluation of hippocampus injury were performed as previously described. 14 The prepared slides (16 μm) were viewed for neurons in the different regions. The mean number of neurons at ×200 magnification (6 sections per brain) was counted manually by an observer blinded to the treatment conditions. The neuronal density loss was estimated according to established method.
16
Assessment of Intracellular MDA Levels
The lipid peroxidation assay kit purchased from Sigma-Aldrich (St Louis, MO) was utilized to measure the MDA level as previously reported.
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Assessment of Nuclear and Mitochondrial Proteins
Nuclear and cytoplasmic extraction reagents and mitochondria isolation kit for tissue were both purchased from Thermo Fisher Scientific (Grand Island, NY). The method for 2 types of extractions was described previously.
18
Statistical Analysis
All experiments were performed with full blinding, allocation concealment, and randomization. Before analysis, Shapiro-Wilk test was used to test the normality and variables were log transformed when necessary. Based on the distribution of normality, Student t test was used to compare the continuous variables after intervention between 2 groups, 1-way ANOVA followed by the Tukey post hoc test were used for when multiple group comparisons were involved (>2 groups) with continuous independent variables, and means±SD were used for expression. If data were not normally distributed even with log transformation, Kruskal-Wallis test followed by the Dunn post hoc test was used for statistics, and the medians (interquartile range) were used for expression. P value of <0.05 was defined as statistically significant. All statistical analyses were performed using SPSS 24.0 (IBM Corp).
Results
Mortality and SAH Severity Scores
Thirty-two rats were part of sham group; 170 rats underwent SAH induction from which 7 rats were excluded. There was no mortality in sham group, and the total mortality in SAH groups was 22.09% (36 of 163; Figure 1A ). Subarachnoid blood clots were observed around the circle of Willis and ventral brain stem 24 hours after SAH ( Figure 
Mitoquinone Treatment Improved Long-Term Neurobehavior and Reduced Hippocampal Neuronopathy
Rotarod test showed a remarkably shorter falling latency in SAH+vehicle group compared with sham group during both the 5 revolutions per minute (39.05 [17.5] Figure 3A ). On the contrary, mitoquinone treatment reversed the poor performance seen in the SAH+vehicle group, and in 10 revolutions per minute (39 [5.11] versus 28.25 [9. 78]) test, the difference was significant (P<0.05; Figure 3A ).
Water maze test results supported spatial memory loss in SAH+vehicle group compared with sham group in terms of longer escape latency and more distance to find the platform, but mitoquinone treatment significantly ameliorated the performance of day 4 to 5 (day 4 escape latency, 24.4 [8.7] Figure 3B ). In probe quadrant trail, compared with sham group, SAH+vehicle group spent more time in wrong quadrants (P<0.05; Figure 3B ). Mitoquinone treatment notably enhanced the duration of time spent in the target quadrant compared with SAH+vehicle group (38.15 [14.26] versus 24.37 [9.07]; P<0.05; Figure 3B ).
Nissl staining and FJC staining revealed more shrinkage in cell morphology and more neuronal loss with cell death in cornu ammonis area (CA)1, CA3, and dentate gyrus of SAH+vehicle group compared with sham group (P<0.05; Figure 3C and 3D). When given mitoquinone treatment, the hippocampal neuronopathies were safeguarded against. Figure 3C and 3D).
Foot fault test revealed deficits in all limbs; especially, amelioration of forelimbs was noted in the SAH+vehicle group compared with sham group for 3 weeks (P<0.05; Figure IV in the online-only Data Supplement). In contrast, mitoquinone treatment improved performance compared with SAH+vehicle group (P<0.05; Figure IV in the online-only Data Supplement).
Mitoquinone Improved Neurobehavior and Activated Mitophagy Through Nrf2 and PHB2 Dependent Pathway
Compared with SAH+DMSO+mitoquinone group, ML385 abolished the protective effects of mitoquinone administration both in modified Garcia (11.5 Figure 4A and 4B). Western blot revealed a significant increase in expression of Keap1, PINK1, Parkin, LC3, and no change in Nrf2, whereas decrease in PHB2 of SAH+vehicle group when compared with sham group (P<0.05; Figure 4C Mortality rate and expression changes of Keap1 (Kelch-like epichlorohydrin-associated protein), Nrf2 (nuclear factor-E2-related factor 2), PHB2 (prohibitin 2), and LC3 after subarachnoid hemorrhage (SAH). A, The number of mortality and excluded rats of each group. *shared groups with experiment 2. B, Representative Western blot images and (C) quantitative analysis of Keap1, Nrf2, PHB2, and LC3 time course expression. n=6 per group. Data of LC3 time course expression was expressed as the medians with interquartile range using Kruskal-Wallis test followed by the Dunn post hoc test. Other data were expressed as the means±SD using 1-way ANOVA followed by the Tukey post hoc test. #P<0.05 vs sham group. DMSO indicates dimethyl sulfoxide; LC3, light chain 3; MitoQ, mitoquinone; and Scr siRNA, scramble small interfering RNA.
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Blockade of Nrf2 and PHB2 Abolished the Protective Effect of Mitoquinone in Oxidative Stress-Induced Neuronal Death
Significantly more positive and DHE-FJC merged cells were shown in SAH+vehicle group, SAH+ML385+mitoquinone group, and SAH+PHB2 siRNA+mitoquinone group compared with their treatment control groups (SAH+mitoquinone group, SAH+DMSO+mitoquinone group, and SAH+ scramble siRNA+mitoquinone group; P<0.05; Figure 5A and 5B). Similar results were also obtained in MDA measurements. Intracellular MDA increased significantly in SAH+vehicle when compared with sham group (P<0.05; Figure 5C ). On administration of mitoquinone, MDA Figure 5C ). In addition, MDA levels in SAH+ML385+mitoquinone (19.57±3.9 versus 9.34±2.62), SAH+PHB2 siRNA+mitoquinone (16.08±1.95 versus 7.78±0.65) groups significantly increased when compared with their treatment control groups (P<0.05; Figure 5C ).
Expression of apoptosis-related proteins showed that Bcl-xl (B-cell lymphoma-extra large) decreased, whereas Bax (B-cell lymphoma-2 associated X protein), Cleaved Caspase-3 increased significantly in SAH+vehicle group compared with sham group (P<0.05; Figure 5D ). Meanwhile, reactive oxygen species-related protein Romo1 (reactive oxygen species modulator 1) also increased notably after SAH (P<0.05; Figure 5D ). Treatment with mitoquinone reversed the aforementioned changes, whereas administration of ML385 and PHB2 siRNA terminated the protective effects of mitoquinone leading to decreased expression of Bcl-xl (0.57±0. 13 Figure 5D ). On analysis of nuclear extraction samples, both Keap1 and Nrf2 increased significantly in SAH+vehicle group compared with sham group (P<0.05; Figure 6A ). Meanwhile, after mitoquinone treatment, Keap1 (1.21±0.6 versus 1.9±0.32) decreased, whereas Nrf2 (2.32±0.29 versus 1.61±0.44) increased when compared with SAH+vehicle group (P<0.05; Figure 6A ). Cytoplasmic extraction samples revealed that expression of Keap1/Nrf2 complex remained as in the whole cell extraction (P<0.05; Figure 6B ). In mitochondrial extraction, expression of PINK1 was significantly increased, whereas PHB2 was decreased in SAH+vehicle group compared with sham group (P<0.05; Figure 6C ). However, mitoquinone treatment group exhibited a further increase in expression of PINK1 (3.06±0.31 versus 2.07±0.53), whereas PHB2 (1.01 [0.6] versus 0.56 [0.29]) expression was reversed when compared with SAH+vehicle group (P<0.05; Figure 6C ). In cytoplasm (except mitochondria) Figure 6D ).
Discussion
Present study revealed that 24 hours after SAH, there is an increase in neuronal expression of Keap1, LC3II, no changes in Nrf2, and a decrease in PHB2. Mitoquinone treatment improved both short-and long-term neurological impairment, attenuated neuronal death, and is associated with upregulation of Nrf2 and PHB2. Inhibition of Nrf2 abolished neurological improvement associated with mitoquinone, which was related to the overexpression of Keap1 and downregulation of Nrf2, PINK1, Parkin, PHB2, and LC3II. Moreover, knockdown of PHB2 using PHB2 siRNA abolished mitoquinone treatment effect in a similar manner as inhibition of Nrf2, which was associated with a decrease of LC3II but did not affect Keap1, Nrf2, PINK1, or Parkin. In addition, we discovered changes in expression of Keap1/Nrf2 complex in the nuclear extraction samples, as well as PINK1, Parkin, PHB2, LC3II component in the mitochondrial extraction. Taken together, our findings suggest that mitoquinone promotes mitophagy, attenuation of oxidative stress-related neuronal death, and associated improvement in neurological impairment through Keap1/Nrf2/ PHB2 pathway after SAH.
Mitoquinone was initially discovered as a mitochondriatargeting antioxidant when compared with cytoplasm-targeted antioxidants, such as Coenzyme Q10. These kind of mitochondria-targeted therapies have a more specific and effective outcome for inhibition of oxidative stress and apoptosis. 7 Recently, mitoquinone was utilized as an effective treatment in kidney injury 9 and received extensive attention because of its neuroprotective effects. 7 However, no research has been published to evaluate mitoquinone as a treatment modality for stroke. In this study, we have discovered that treatment with mitoquinone has the capacity to attenuate oxidative stress and neuronal 
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death, both short-term and long-term after SAH. At same time, we found a reasonable mechanism for how mitoquinone and mitophagy improve neurological function. In addition, liposoluble mitoquinone can easily bypass the blood-brain barrier, 7 thereby allowing utilization of intraperitoneal injection, which is more suitable for clinical application. To address a previously reported concern about a prooxidant effect being associated with higher concentrations of mitoquinone, 19 we used 3 different dosages in our investigation of treatment for SAH. Our results suggest that 3 mg/kg of mitoquinone is most effective for neurological recovery. Although higher concentrations of mitoquinone may not result in an increase in its therapeutic effects, it is also important to note that 3× our recommended dosage (9 mg/kg) did not make the outcome worse than that seen in the SAH+vehicle group. Thus, appropriate dosage of mitoquinone is beneficial for treatment of SAH in rats.
Keap1/Nrf2 complex is a well-documented target of the antioxidant signaling pathway. 20 During homeostasis, Nrf2 remains in the cytoplasm and is degraded by Keap1. After acute stress, the junction between the 2 complexes is disrupted, allowing Nrf2 to increase rapidly and translocate to the nucleus for transcriptional activities. 21 Our present investigation concurred that Keap1 increased gradually, which mediated degradation of Nrf2 in both the cytoplasm and the nucleus. However, on administration of mitoquinone, Keap1 decreased dramatically, and more Nrf2 transmitted into the nucleus for antioxidant response. Keap1 contains several cysteine residues for specific electrophiles or unique sets to target. It is our hypothesis that mitoquinone may bind to Keap1 for degradation and improve the function of Nrf2.
Neuronal autophagy occurs with stroke, as well as SAH; therefore, mitophagy, a mitochondria-targeted autophagy, is assumed to be involved. 22 The PINK1/Parkin-mediated pathway is the most well-known mitophagy pathway, which is associated with the Keap1/Nrf2 complex. 9 In physiological conditions, PINK1 is continuously imported into mitochondria for degradation; however, it will accumulate on the outer membrane of mitochondria during oxidative stress. 11 At the same time, Parkin is recruited from the cytoplasm to mitochondria for activation, which promotes mitophagy. 11 It has been recently discovered that a novel mitochondrial protein called PHB2 serves as a receptor of mitophagy, it binds to LC3II with its LC3-interaction domain, which then results in Parkin induced outer membrane rupture. 10 Thus, we hypothesized that PHB2 may serve as a downstream protein of the PINK1/Parkin pathway. In the present investigation, we found that PINK1, Parkin, and LC3II were enhanced after SAH, which proved the theory of activation of mitophagy in a SAH model. However, when separating the mitochondrial fraction, activation was not that significant, and mitophagy receptor PHB2 was found to decrease after SAH. It means that mitophagy is insufficient in SAH induction and that the relationship between PINK1/Parkin pathway and PHB2 is not one of simple positive regulation. Our study revealed an increase in oxidative stress-stimulated deaths of cells after SAH and poor outcomes associated with administration of PHB2 siRNA. It was our aim to prove our hypothesis that stable PHB2, which is normally located in the inner membrane of mitochondria, is exposed during mitophagy to promote clearance of damaged mitochondria to encourage , and LC3 mitochondrial expressions; Parkin and LC3 cytoplasmic (except mitochondria) plus nuclear expressions were expressed as the medians with interquartile range using Kruskal-Wallis test followed by the Dunn post hoc test. Other data were expressed as the means±SD using 1-way ANOVA followed by the Tukey post hoc test. #P<0.05 vs sham group; *P<0.05 vs SAH+vehicle group. LC3, Light chain 3; Histone 3 was used for nuclear protein marker; CoxIV (Cyclooxygenase-IV) was used for mitochondrial protein marker.
survival of other mitochondria. However, if the cells suffer severe damage, such as oxidative stress, mitophagy would not be effective, and mitochondria would inevitably undergo apoptosis. An increase in mitochondrial death would lead to a dramatic decrease in PHB2.
Oxidative stress and apoptosis are essential factors that play a significant role in EBI. 2 Studies reveal that mitochondrial dysfunction is strongly associated with reactive oxygen species generation, the accumulation of which may directly deplete the mitochondrial membrane potential and lead to neuronal death. 23 Our investigation demonstrates that mitoquinone promotes mitophagy, improves mitochondrial function, and thereby attenuates oxidative stress-related apoptosis. It has been previously reported that Romo1 is a marker of mitochondrial oxidative stress. 24 The results of our investigation not only support the association between oxidative stress and Romo1 but also underscore the importance of Bcl-xl, other than Bcl-2, as critical factor in this dynamic relationship. 25 A recent study reported the presence of hippocampal injury 24 hours after SAH. 26 Our study also supports widely distributed neuronal death in the hippocampus, especially in CA1, CA3, and dentate gyrus regions in long-term SAH rats, whereas mitoquinone has the capacity to reverse this harmful effect. As we only administered 1 dose of treatment, the long-term improvement seen with mitoquinone use is likely because of its effect on EBI.
The results of our investigation support mitoquinone as treatment to promote mitophagy to attenuate oxidative stressrelated neuronal death. However, there are limitations. First, although PHB2 locates in the mitochondria, it has also been reported that it can modulate the mitochondrial fusion protein OPA1 (optic atrophy 1) for mitochondrial dynamic regulation. 27 Second, because of the limitation of LC3B antibody, we only tested LC3II in Western blot but not with immunofluorescence. In addition, there may be other factors that influence the protective effects of mitoquinone on mitophagy, which must be further investigated.
In conclusion, we demonstrated that mitoquinone is able to promote mitophagy and attenuate mitochondrial oxidative stress-related neuronal apoptosis through Keap1/Nrf2/PHB2 pathway in EBI after SAH, which is associated with improvement in short-term and long-term neurological impairment. Mitoquinone may, therefore, be useful as a therapeutic antioxidant against EBI, as well as treatment for delayed neurological deficits after SAH.
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